Is NBTX a Buy? What to Consider in 2026

Short answer

The bull case for NBTX (NBTX) rests on Johnson & Johnson partnership: J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the pivotal Phase 3 program, validating the science and de-risking spend. Revenue (FY2025) is ~$36M (~EUR 32.6M, largely J&J-agreement, non-product). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. Whether NBTX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Nanobiotix S.A. is a clinical-stage nanomedicine company headquartered in France and dual-listed on Nasdaq (as American Depositary Shares under NBTX) and Euronext Paris. Its lead product candidate, NBTXR3 (also called JNJ-1900), is a radioenhancer: injectable nanoparticles that are placed directly into a tumor and, when activated by standard radiotherapy, are designed to boost the radiation's tumor-killing effect. In late 2023 the company signed a global license and collaboration with Johnson & Johnson's Janssen unit, which now sponsors and operates the pivotal Phase 3 NANORAY-312 study in head and neck cancer and broader development across other solid tumors. As a pre-revenue-product biotech, Nanobiotix has no approved drug and its reported revenue comes largely from the J&J agreement rather than from selling a product, so the investment picture is defined by pipeline milestones and cash runway rather than earnings. The bull case rests on NBTXR3 succeeding in head and neck cancer plus expansion signals in lung and other tumors, unlocking large milestone and royalty payments from J&J. The bear case is the standard clinical-biotech risk: a failed or delayed Phase 3, further dilution, and a valuation (roughly $1.5 billion in mid-2026) that already prices in meaningful clinical success years before any approval.

What's the case for buying NBTX?

1. Johnson & Johnson partnership

J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the pivotal Phase 3 program, validating the science and de-risking spend. The deal carries potential milestone payments reported around $1.77 billion for the first programs plus royalties, so success would deliver large non-dilutive cash flows. Having a large-cap pharma sponsor also lends operational scale that a small biotech could not fund alone.

2. NANORAY-312 head and neck readout

NANORAY-312 is the registrational Phase 3 study in locally advanced head and neck squamous cell carcinoma, now J&J-sponsored, and its data is the single biggest catalyst for the stock. Management amended the design to remove the interim analysis and pull the final analysis forward, with a readout expectation communicated for the 2026 to 2027 window. A positive result would open a U.S. regulatory filing and a first potential approval.

3. Pipeline expansion beyond head and neck

Early Phase 2 CONVERGE data in stage 3 inoperable non-small cell lung cancer showed an encouraging overall response rate (around 85.7 percent in a very small initial patient group) when NBTXR3 was combined with chemoradiotherapy and immunotherapy. Additional tumor types and an Asia collaboration (LianBio) broaden the addressable opportunity. Each new indication is optionality layered on top of the core head and neck program.

4. Extended cash runway

After a roughly 86 million euro follow-on offering in May 2026 on top of prior royalty financing, the company has guided to a cash runway reaching toward 2029. A longer runway reduces the near-term risk of a forced, deeply dilutive raise ahead of key data. It gives Nanobiotix room to reach pivotal readouts without an urgent financing overhang.

What are the risks to NBTX?

The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. As a clinical-stage biotech, Nanobiotix funds itself through partnership payments and equity raises, so continued losses and further share dilution are likely until (and unless) a product is approved. The valuation of roughly $1.5 billion already embeds substantial expectation of success, leaving little margin for disappointment. Concentration is acute because a large share of value depends on one molecule and one partner, so a strategic shift by J&J would be highly damaging. Being a foreign issuer listed via ADS also adds currency, reporting-timing, and liquidity considerations for U.S. holders.

How is NBTX valued? (as of July 2026)

Price

$37.39

Market cap

$1.90B

Forward P/E

483.49

Beta

0.56

52-week range

$4.93 to $57.14

Snapshot for NBTX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Market cap: ~$1.5B
Revenue (FY2025): ~$36M (~EUR 32.6M, largely J&J-agreement, non-product)
Net loss (FY2025): ~$26M (~EUR 24.0M)
Cash (Dec 31, 2025): ~$58M (~EUR 52.8M)
May 2026 equity raise: ~$95M (~EUR 86.1M)
Cash runway guidance: ~into 2029

Standard price-to-earnings valuation does not apply because Nanobiotix is pre-approval and its reported revenue stems mostly from the J&J agreement rather than product sales. The market instead prices the probability-weighted value of NBTXR3 across head and neck, lung, and other tumors, net of dilution risk. That is why the roughly $1.5 billion market value sits far above trailing revenue and coexists with ongoing net losses.

How do you decide if NBTX is a buy?

Rather than asking whether NBTX is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold NBTX indirectly through an index or sector ETF before adding more.

For the full picture, see the NBTX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NBTX against your real portfolio and see your actual exposure before deciding.

The bottom line on NBTX

The bottom line: NBTX's story right now is Johnson & Johnson partnership, with revenue (fy2025) at ~$36M (~EUR 32.6M, largely J&J-agreement, non-product). If you believe that narrative continues, the call is about sizing NBTX sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around NBTX with Walnut

Use NBTX as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is NBTX a good stock to buy right now?

The case for NBTX right now is Johnson & Johnson partnership, with revenue (fy2025) at ~$36M (~EUR 32.6M, largely J&J-agreement, non-product). If you believe that thesis holds, NBTX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does NBTX do?

Nanobiotix S.A.

What are the main risks of NBTX?

What does Nanobiotix (NBTX) actually do?

It is a clinical-stage nanomedicine company developing NBTXR3, injectable nanoparticles placed inside a tumor that are activated by standard radiotherapy to enhance the radiation's cancer-killing effect. It has no approved product yet and is focused on late-stage cancer trials.

What is the Johnson & Johnson partnership?

J&J's Janssen unit holds a global license to NBTXR3 (branded JNJ-1900) and now sponsors and funds most of the pivotal Phase 3 program. The collaboration includes potential milestone payments (reported around $1.77 billion for first programs) plus royalties if the drug is approved and sold.

What is NANORAY-312?

NANORAY-312 is the registrational Phase 3 trial testing NBTXR3 in locally advanced head and neck squamous cell carcinoma. It is J&J-sponsored, was amended to remove the interim analysis and accelerate the final analysis, and its data is the single most important catalyst for the stock.

Is NBTX profitable?

No. As of full-year 2025 it reported a net loss of roughly 24 million euros, and its revenue comes mainly from the J&J agreement rather than product sales. As a pre-approval biotech it is expected to keep operating at a loss until a product reaches the market.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NBTX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.